29 July 2021Big PharmaAlex Baldwin
Is big pharma’s antidote to the COVID-19 waiver a viable alternative?
In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
17 May 2021 The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021 UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).
Editor's picks
Editor's picks
Big Pharma
17 May 2021 The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021 UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).
Big Pharma
17 May 2021 The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Big Pharma
25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
Big Pharma
28 October 2021 UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).